文献速递神经免疫

无疾病活动证据与多发性硬化无长期残疾进展的相关性:系统综述与Meta分析

Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2022-07-11

该系统综述与Meta分析检索2006年1月1日至2021年1月26日的MEDLINE、Embase和Cochrane数据库,纳入29项研究(27项进入Meta分析,N=10,935),评估复发缓解型多发性硬化患者1或2年时NEDA-3与长期无残疾进展的关系,发现NEDA-3与低效和高疗效治疗下无长期残疾进展均相关。

要点

  • NEDA-3 vs EDA无进展的合并OR:低效治疗2.32(95%CI 1.58-3.42;I²=73%),高效治疗3.19(95%CI 1.86-5.47;I²=86%)。
  • 随访无进展患病率>80%的研究中,NEDA-3的PPV低效治疗91%(95%CI 89%-93%),高效治疗92%(95%CI 88%-94%)。
  • 随访无进展患病率≤80%的研究中,PPV低效治疗81%(95%CI 75%-86%),高效治疗86%(95%CI 80%-90%)。

核心结论

  • NEDA-3与复发缓解型多发性硬化在低效和高疗效治疗下的无长期残疾进展均相关。
  • 作者认为,结合易测量生物标志物的早期复合结局指标及更长随访的进一步研究可能有助于提高NEDA-3在RRMS中的预后价值。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane数据库2006年1月1日至2021年1月26日。
  • 纳入评估1或2年时NEDA-3且随访至少4年以判定残疾进展的研究。
  • 定性合成纳入29项研究,其中27项(低效16项、高效11项)进入Meta分析,N=10,935名参与者。
  • 中位随访5.6年(四分位距4.3-8.0年),采用随机效应模型进行Meta分析。

主要发现

  • NEDA-3 vs EDA无残疾进展的合并OR:低效治疗2.32(95%CI 1.58-3.42;I²=73%),高效治疗3.19(95%CI 1.86-5.47;I²=86%)。
  • 随访无进展患病率>80%的研究中,NEDA-3对无残疾进展的合并PPV:低效治疗91%(95%CI 89%-93%),高效治疗92%(95%CI 88%-94%)。
  • 随访无进展患病率≤80%的研究中,合并PPV:低效治疗81%(95%CI 75%-86%),高效治疗86%(95%CI 80%-90%)。

关键数值与推荐

  • NEDA-3定义为无复发、无新MRI病灶且无确认的残疾进展。
  • 主要结局无残疾进展定义为随访期间扩展残疾状态量表上无确认进展。
  • PPV按随访无进展患病率>80% vs ≤80%分别汇总。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 低效治疗合并OR的异质性I²=73%。
  • 高效治疗合并OR的异质性I²=86%。
  • 作者提出需进一步研究结合易测量生物标志物的早期复合结局指标及更长随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We conducted a systematic review and meta-analysis to evaluate the relationship between no evidence of disease activity (NEDA) and no long-term disability progression on low- and high-efficacy therapy in relapsing-remitting multiple sclerosis (RRMS). METHODS: MEDLINE, Embase, and the Cochrane Database were searched from January 1, 2006, to January 26, 2021. We selected studies that evaluated NEDA-3 (no relapse, new MRI lesion, or confirmed disability progression) at 1 or 2 years and had a minimum of 4 years of follow-up for determination of disability progression. Data were extracted by 2 independent reviewers and were meta-analyzed with a random-effects model. Primary outcome of no disability progression was defined as no confirmed progression on the Expanded Disability Status Scale during follow-up. We assessed the odds ratio (OR) for no disability progression with NEDA vs evidence of disease activity (EDA). Positive predictive value (PPV) of NEDA for no disability progression was summarized for studies with prevalence of no progression >80% vs ≤80% separately. RESULTS: We included 29 studies in our qualitative synthesis, of which 27 (16 low efficacy, 11 high efficacy) were included in the meta-analysis (N = 10,935 participants). Median follow-up was 5.6 years (interquartile range 4.3-8.0 years). The pooled ORs for no progression with NEDA-3 vs EDA were 2.32 (95% CI 1.58-3.42; I 2 = 73%) for low-efficacy therapy and 3.19 (95% CI 1.86-5.47; I 2 = 86%) for high-efficacy therapy. Among studies with prevalence of no progression at follow-up >80%, the pooled PPV for low efficacy therapy was 91% (95% CI 89%-93%) and for high-efficacy therapy was 92% (95% CI 88%-94%). Among studies with prevalence of no progression ≤80%, the pooled PPV for low-efficacy therapy was 81% (95% CI 75%-86%) and for high-efficacy therapy was 86% (95% CI 80%-90%). DISCUSSION: NEDA-3 is associated with no long-term disability progression in RRMS on both low- and high-efficacy therapies. Further studies of early composite outcome measures incorporating easily measurable biomarkers and longer follow-up may help to improve the prognostic value of NEDA-3 in RRMS. TRIAL REGISTRATION INFORMATION: International Prospective Register of Systematic Reviews Identifier: CRD42020189316.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rotstein D, Solomon JM, Sormani MP, et al. Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis. Neurology. 2022. PMID: 35473761. doi:10.1212/WNL.0000000000200549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。